Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Christoph Kornauth, Tea Pemovska, PhDMSc,BSc, Gregory Ian Vladimer, PhD, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, Harald Esterbauer, MD PhD, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, MSc, Alexander Gaiger, Hildegard T. Greinix, MD, Wolfgang Gstöttner, Marcus Hacker, Alexander Hauswirth, MD, Tim Heinemann, Daniel Heintel, Mir Ali Reza Hoda, Ulrich Jaeger, Lukas Kazianka, MD, Lukas Kenner, MD, Barbara Kiesewetter, MD, Nikolaus Krall, PhD, Trang Le, BSc, Simone Lubowitzki, Marius E Mayerhoefer, Elisabeth Menschel, Olaf Merkel, PhD, Katsuhiro Miura, MD PhD, Leonhard Muellauer, MD PhD, Peter Neumeister, MD, Thomas Noesslinger, MD, Katharina Ocko, Leopold Öhler, Michael Panny, MD, Alexander Pichler, MD, Edit Anna Porpaczy, MD, Gerald Prager, MD, Markus Raderer, Robin Ristl, Reinhard Ruckser, MD, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, MD, Ilse Schwarzinger, MD, Edgar Selzer, Cathrin Skrabs, Wolfgang R. Sperr, MD, Ismet Srndic, MSc, Renate Thalhammer, MD, Peter Valent, MD, Emiel van der Kouwe, PharmD, Katrina Vanura, PhD, Stefan Vogt, Cora Waldstein, Dominik Wolf, Univ. Prof. Dr., Christoph Zielinski, Ingrid Simonitsch-Klupp, MD, Giulio Superti-Furga, PhD, Berend Snijder, PhD, Philipp B. Staber, MD PhD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140831

Published: 2020

Journal Articles

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

Philipp Bernhard Staber, MD PhD, Christoph Kornauth, Ines Garces de los Fayos Alonso, Wilhelm Woessmann, MD, Wolfram Klapper, Sabine Lagger, Ana-Iris Schiefer, Cathrin Skrabs, Olaf Merkel, PhD, Marius E Mayerhoefer, Richard Greil, MD, Ingrid Simonitsch-Klupp, MD, Lukas Kenner, MD, Ulrich Jaeger, MD

Blood (2019) 134 (Supplement_1): 4037.

https://doi.org/10.1182/blood-2019-129955

Published: 2019

Journal Articles

External Validation and Revision of Thrombosis Lymphoma /Throly/ Score

Darko Antic, PhD, Natasa Milic, Biljana Mihaljevic, Bruce Cheson, MD, Mayur Narkhede, MD, Hikmat Abdel-Razeq, Irina Panovska, Sanja Trajkova, Marija Popova, Igor Aurer, Ana Boban, Michele Ghielmini, Alden Moccia, Aurelien Delluc, Jean-Christophe Ianotto, Ulrich Jaeger, MD, Cathrin Skrabs, Grigorios T. Gerotziafas, Jawed Fareed, PhD

Blood (2018) 132 (Supplement 1): 140.

https://doi.org/10.1182/blood-2018-99-115568

Published: 2018

Journal Articles

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

Blood (2018) 132 (7): 694–706.

https://doi.org/10.1182/blood-2017-10-810739

Published: 2018

Includes: Supplemental data

Journal Articles

JAK2-Inhibitor Therapy Associated Lymphomas in Myelofibrosis: Distinct Clinico-Pathological Features Recapitulated in a Mouse Model

Blood (2017) 130 (Supplement 1): 1643.

https://doi.org/10.1182/blood.V130.Suppl_1.1643.1643

Published: 2017

Journal Articles

Integrated ATAC-Seq and Chemosensitivity Profiling Identifies Rational Drug Combinations in Ibrutinib-Treated CLL Patients

Blood (2017) 130 (Supplement 1): 800.

https://doi.org/10.1182/blood.V130.Suppl_1.800.800

Published: 2017

Journal Articles

Ristocetin-Induced Platelet Aggregation for Monitoring of Bleeding Tendency in Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia

Lukas Kazianka, Christa Drucker, Cathrin Skrabs, MD, Philipp Bernhard Staber, MD PhD, Edit Anna Porpaczy, MD PhD, Christine Einberger, Marion Heinz, Alexander Hauswirth, MD, Ingrid Pabinger, MD, Peter Quehenberger, MD, Bernd Jilma, MD, Ulrich Jaeger, MD

Blood (2015) 126 (23): 718.

https://doi.org/10.1182/blood.V126.23.718.718

Published: 2015

Journal Articles

Rituximab Maintenance Significantly Prolongs Event Free (EFS) and Progression Free Survival (PFS) In Male Patients With Aggressive B-Cell Lymphoma In The NHL13 Study

Blood (2013) 122 (21): 851.

https://doi.org/10.1182/blood.V122.21.851.851

Published: 2013

Journal Articles

Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia

Michaela Gruber, Judith Bellemare, Gregor Hoermann, Andreas Gleiss, Edit Porpaczy, Martin Bilban, Trang Le, Sonja Zehetmayer, Christine Mannhalter, Alexander Gaiger, Medhat Shehata, Karin Fleiss, Cathrin Skrabs, Éric Lévesque, Katrina Vanura, Chantal Guillemette, Ulrich Jaeger

Blood (2013) 121 (7): 1175–1183.

https://doi.org/10.1182/blood-2012-08-447359

Published: 2013

Includes: Supplemental data

Journal Articles

Cannabinoid Receptor 1 in Chronic Lymphocytic Leukemia: Strong Prognostic Marker with Limited Therapeutic Use

Patricia Weiss, Edit Anna Porpaczy, MD, Trang Le, Cathrin Skrabs, Michaela Gruber, Clemens Pausz, Ulrich Jäger, Katrina Vanura

Blood (2012) 120 (21): 4565.

https://doi.org/10.1182/blood.V120.21.4565.4565

Published: 2012

Journal Articles

A New Prognostic Score for Aggressive B-Cell Lymphoma with C-MYC Translocation Integrating Clinical and Genetic Features.

Ana-Iris Schiefer, Michael Melcher, Zsuzsanna Bago-Horvath, Sandra Eder, Cathrin Skrabs, Alexander Hauswirth, Berthold Streubel, M.D., Christine Mannhalter, Dagmar Stoiber, Veronika Sexl, MD, Leonhard Müllauer, Ulrich Jaeger, MD, Edit Anna Porpaczy, MD

Blood (2012) 120 (21): 2685.

https://doi.org/10.1182/blood.V120.21.2685.2685

Published: 2012

Journal Articles

Two-Monthly Rituximab Infusions Maintain Target Concentrations: Pharmacokinetic Data of the AGMT-NHL9 Maintenance Study in Patients with Follicular Lymphoma in Complete or Partial Remission.

Ulrich Jaeger, MD, Otto Krieger, MD, Georg Hopfinger, MD, Cathrin Skrabs, MD, Christine Einberger, Veronika Huter, MD, Hubert Hausmaninger, MD, Johannes Drach, MD, Markus Raderer, MD, Michael Woo, Pharm.D, Helen Melzer, PhD, Richard Greil, MD, Michael A Fridrik, MD

Blood (2008) 112 (11): 1997.

https://doi.org/10.1182/blood.V112.11.1997.1997

Published: 2008

Journal Articles

Identification of Genes Associated with Resistance and Response in Vivo to Therapy with Rituximab, Fludarabine and Cyclophosphamide in Patients with Chronic Lymphocytic Leukemia.

Blood (2008) 112 (11): 1622.

https://doi.org/10.1182/blood.V112.11.1622.1622

Published: 2008

Journal Articles

Predictive Value of Clonal Peripheral Blood γTCR Rearrangement in Patients with Peripheral T-Cell Lymphoma.

Christian Schuetzinger, Harald Esterbauer, MD,PhD, Cathrin Skrabs, MD, Martin Uffmann, MD, Markus Raderer, MD, Alexander Hauswirth, MD, Alexander Gaiger, MD, Christine Mannhalter, PhD, Karin Dieckmann, MD, Oswald Wagner, MD, Ulrich Jaeger, MD

Blood (2006) 108 (11): 2060.

https://doi.org/10.1182/blood.V108.11.2060.2060

Published: 2006

NARROW

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

External Validation and Revision of Thrombosis Lymphoma /Throly/ Score

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

JAK2-Inhibitor Therapy Associated Lymphomas in Myelofibrosis: Distinct Clinico-Pathological Features Recapitulated in a Mouse Model

Integrated ATAC-Seq and Chemosensitivity Profiling Identifies Rational Drug Combinations in Ibrutinib-Treated CLL Patients

Ristocetin-Induced Platelet Aggregation for Monitoring of Bleeding Tendency in Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia

Rituximab Maintenance Significantly Prolongs Event Free (EFS) and Progression Free Survival (PFS) In Male Patients With Aggressive B-Cell Lymphoma In The NHL13 Study

Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia

Cannabinoid Receptor 1 in Chronic Lymphocytic Leukemia: Strong Prognostic Marker with Limited Therapeutic Use

A New Prognostic Score for Aggressive B-Cell Lymphoma with C-MYC Translocation Integrating Clinical and Genetic Features.

Two-Monthly Rituximab Infusions Maintain Target Concentrations: Pharmacokinetic Data of the AGMT-NHL9 Maintenance Study in Patients with Follicular Lymphoma in Complete or Partial Remission.

Identification of Genes Associated with Resistance and Response in Vivo to Therapy with Rituximab, Fludarabine and Cyclophosphamide in Patients with Chronic Lymphocytic Leukemia.

Predictive Value of Clonal Peripheral Blood γTCR Rearrangement in Patients with Peripheral T-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only